13/02/2026
For years, MSF's own experience of responding to infectious disease outbreaks, epidemics and pandemics has shown that patients and communities who contribute vital samples, data, and clinical participation to lifesaving innovations are too often left behind and denied access to the very products they help make possible. MSF has advocated for the WHO Pandemic Agreement to establish a multilateral system that ensures fair and equitable benefit-sharing in exchange for access to pathogens and genetic resources used in research and development (R&D), including clinical trials. Read MSF’s recent recommendations for a strong and effective WHO Pathogen Access and Benefit-Sharing (PABS) System capable of delivering reliable, equitable, and accountable access to vaccines, diagnostics, and treatments developed from shared samples and data.
MSF recommendations on WHO Pathogen Access and Benefit-Sharing (PABS) systems